|
業務類別
|
Biotechnology |
|
業務概覽
|
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |
| 公司地址
| 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 624-1100 |
| 傳真號碼
| +1 650 624-1101 |
| 公司網頁
| https://www.rigel.com |
| 員工數量
| 164 |
| Mr. Raymond J. Furey |
Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
美元 462.00K |
10/04/2025 |
| Mr. David A. Santos |
Executive Vice President and Chief Commercial Officer |
美元 496.08K |
10/04/2025 |
| Ms. Lisa Rojkjaer |
Executive Vice President and Chief Medical Officer |
美元 401.25K |
10/04/2025 |
| Mr. Dean L. Schorno |
Chief Financial Officer |
美元 495.10K |
03/03/2026 |
| Mr. Raul R. Rodriguez |
Director and Chief Executive Officer |
美元 757.00K |
03/03/2026 |
|
|
| Ms. Kamil Ali-Jackson, Esq. |
Independent Director |
03/03/2026 |
| Dr. Alison L. Hannah, M.D. |
Independent Director |
03/03/2026 |
| Mr. Gregg Anthony Lapointe, C.P.A.,M.B.A. |
Chairman of the Board |
03/03/2026 |
| Dr. Walter H. Moos,PhD |
Independent Director |
03/03/2026 |
| Mr. Raul R. Rodriguez |
Director and Chief Executive Officer |
03/03/2026 |
| Ms. Jane Wasman, J.D. |
Independent Director |
03/03/2026 |
| Dr. Mark W. Frohlich M.D. |
Independent Director |
03/03/2026 |
| Mr. Michael P. Miller |
Independent Director |
03/02/2026 |
|
|
|
|
